相似文献
1
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
Drug Resist Updat. 2008 Feb-Apr;11(1-2):17-24. doi: 10.1016/j.drup.2008.02.001. Epub 2008 Apr 18.
2
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Cancer Treat Rev. 2009 May;35(3):280-8. doi: 10.1016/j.ctrv.2008.11.006. Epub 2008 Dec 30.
3
Modulation of death receptor pathways in oncology.
Drugs Today (Barc). 2003;39 Suppl C:95-109.
4
Safety and tolerability of TRAIL receptor agonists in cancer treatment.
Eur J Clin Pharmacol. 2015 May;71(5):525-7. doi: 10.1007/s00228-015-1823-1. Epub 2015 Feb 24.
5
Onto better TRAILs for cancer treatment.
Cell Death Differ. 2016 May;23(5):733-47. doi: 10.1038/cdd.2015.174. Epub 2016 Mar 4.
6
TRAIL as a target in anti-cancer therapy.
Cancer Lett. 2009 Nov 18;285(1):1-5. doi: 10.1016/j.canlet.2009.02.029. Epub 2009 Mar 18.
7
Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
Future Oncol. 2021 Feb;17(5):581-596. doi: 10.2217/fon-2020-0727. Epub 2021 Jan 6.
8
Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.
9
The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.
Biomed Pharmacother. 2018 Nov;107:1010-1019. doi: 10.1016/j.biopha.2018.08.065. Epub 2018 Aug 24.
10
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
Eur J Pharmacol. 2009 Dec 25;625(1-3):63-72. doi: 10.1016/j.ejphar.2009.06.066. Epub 2009 Oct 18.
引用本文的文献
1
Chemical synthetic approaches to mimic the TRAIL: promising cancer therapeutics.
RSC Med Chem. 2024 Aug 1;15(11):3639-51. doi: 10.1039/d4md00183d.
2
Roles of Krüppel-like factor 6 splice variant 1 in the development, diagnosis, and possible treatment strategies for non-small cell lung cancer.
Am J Cancer Res. 2022 Oct 15;12(10):4468-4482. eCollection 2022.
3
A research update on the antitumor effects of active components of Chinese medicine ChanSu.
Front Oncol. 2022 Sep 27;12:1014637. doi: 10.3389/fonc.2022.1014637. eCollection 2022.
4
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A.
iScience. 2022 Jun 3;25(7):104518. doi: 10.1016/j.isci.2022.104518. eCollection 2022 Jul 15.
5
TR35 Exerts Anti-tumor Effects by Modulating Mitogen-Activated Protein Kinase and STAT3 Signaling in Lung Cancer Cells.
Front Cell Dev Biol. 2021 Oct 25;9:723346. doi: 10.3389/fcell.2021.723346. eCollection 2021.
6
Sensitizing TRAIL‑resistant A549 lung cancer cells and enhancing TRAIL‑induced apoptosis with the antidepressant amitriptyline.
Oncol Rep. 2021 Jul;46(1). doi: 10.3892/or.2021.8095. Epub 2021 Jun 3.
7
Self-assembled peptide nanostructures targeting death receptor 5 and encapsulating paclitaxel as a multifunctional cancer therapy.
ACS Biomater Sci Eng. 2019 Nov 11;5(11):6046-6053. doi: 10.1021/acsbiomaterials.9b01259. Epub 2019 Oct 23.
8
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
Front Oncol. 2020 Jul 22;10:1067. doi: 10.3389/fonc.2020.01067. eCollection 2020.
9
The MUDENG Augmentation: A Genesis in Anti-Cancer Therapy?
Int J Mol Sci. 2020 Aug 4;21(15):5583. doi: 10.3390/ijms21155583.
10
Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL.
Int J Med Sci. 2019 Sep 20;16(11):1412-1423. doi: 10.7150/ijms.34398. eCollection 2019.
本文引用的文献
1
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
Oncogene. 2008 Jun 19;27(27):3845-55. doi: 10.1038/onc.2008.6. Epub 2008 Feb 4.
2
TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.
J Clin Invest. 2008 Jan;118(1):100-10. doi: 10.1172/JCI33061.
3
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.
J Clin Invest. 2008 Jan;118(1):111-23. doi: 10.1172/JCI29900.
4
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
Br J Haematol. 2007 Nov;139(4):568-77. doi: 10.1111/j.1365-2141.2007.06852.x. Epub 2007 Oct 8.
5
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598.
6
Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Leukemia. 2008 Mar;22(3):652-5. doi: 10.1038/sj.leu.2404956. Epub 2007 Sep 20.
7
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Nat Med. 2007 Sep;13(9):1070-7. doi: 10.1038/nm1627. Epub 2007 Sep 2.
8
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Blood. 2007 Dec 1;110(12):4037-46. doi: 10.1182/blood-2007-02-076075. Epub 2007 Aug 27.
9
The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer.
Clin Lung Cancer. 2007 Jul;8(7):413-9. doi: 10.3816/CLC.2007.n.024.
10
A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
Cancer Res. 2007 Aug 1;67(15):7327-34. doi: 10.1158/0008-5472.CAN-06-4766.
Zotero 插件